Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis—report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412.
PubMed PubMed Central Google Scholar
2.Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
3.Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008;154(3):557–68.
CAS PubMed PubMed Central Google Scholar
4.Taillandier D, Polge C. Skeletal muscle atrogenes: From rodent models to human pathologies. Biochimie. 2019;166:251–69.
5.Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006;119(6):526.e9–17.
6.Morgan SA, Hassan-Smith ZK, Doig CL, Sherlock M, Stewart PM, Lavery GG. Glucocorticoids and 11β-HSD1 are major regulators of intramyocellular protein metabolism. J Endocrinol. 2016;229(3):277–86.
CAS PubMed PubMed Central Google Scholar
7.Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun. 2003;300(4):965–71.
8.Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017;36(1):49–64.
9.European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172–93.
10.Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016;65(6):1232–44.
PubMed PubMed Central Google Scholar
11.Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol. 2019;54(10):845–59.
PubMed PubMed Central Google Scholar
12.Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 2015;31(1):193–9.
13.Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JXQ, et al. Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis. Clin Transl Gastroenterol. 2015;6(7):e102–e.
PubMed PubMed Central Google Scholar
14.van Ginneken BTJ, van den Berg-Emons RJG, Kazemier G, Metselaar HJ, Tilanus HW, Stam HJ. Physical fitness, fatigue, and quality of life after liver transplantation. Eur J Appl Physiol. 2007;100(3):345–53.
PubMed PubMed Central Google Scholar
15.Dhaliwal A, Williams FR, El-sherif O, Armstrong MJ. Sarcopenia in Liver Transplantation: an Update. Curr Hepatol Rep. 2020;19(2):128–37.
16.Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology (Baltimore, Md). 2001;33(2):464–70.
17.Tsien C, Davuluri G, Singh D, Allawy A, Ten Have GAM, Thapaliya S, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology (Baltimore, Md). 2015;61(6):2018–29.
CAS PubMed Central Google Scholar
18.Hassan-Smith ZK, Morgan SA, Sherlock M, Hughes B, Taylor AE, Lavery GG, et al. Gender-Specific Differences in Skeletal Muscle 11beta-HSD1 Expression Across Healthy Aging. J Clin Endocrinol Metab. 2015;100(7):2673–81.
19.Scaldaferri F, Pizzoferrato M, Lopetuso LR, Musca T, Ingravalle F, Sicignano LL, et al. Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. Gastroenterol Res Pract. 2017;2017:8646495.
CAS PubMed PubMed Central Google Scholar
20.Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D. Sarcopenia and Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2018;25(1):67–73.
21.Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, et al. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017;66(4):588–96.
22.Grimstad T, Norheim KB, Isaksen K, Leitao K, Hetta AK, Carlsen A, et al. Fatigue in Newly Diagnosed Inflammatory Bowel Disease. J Crohns Colitis. 2015;9(9):725–30.
23.Pizzoferrato M, de Sire R, Ingravalle F, Mentella MC, Petito V, Martone AM, et al. Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center. Nutrients. 2019;11(10):2281.
CAS PubMed Central Google Scholar
24.Dhaliwal A, Quinlan JI, Overthrow K, Greig C, Lord JM, Armstrong MJ, et al. Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview. Nutrients. 2021;13(2):656.
CAS PubMed PubMed Central Google Scholar
25.Bamba S, Sasaki M, Takaoka A, Takahashi K, Imaeda H, Nishida A, et al. Sarcopenia is a predictive factor for intestinal resection in admitted patients with Crohn's disease. PLoS One. 2017;12(6):e0180036–e.
PubMed PubMed Central Google Scholar
26.van Langenberg DR, Gatta PD, Hill B, Zacharewicz E, Gibson PR, Russell AP. Delving into disability in Crohn's disease: Dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease☆. J Crohn's Colitis. 2014;8(7):626–34.
27.Subramaniam K, Fallon K, Ruut T, Lane D, McKay R, Shadbolt B, et al. Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease. Aliment Pharmacol Ther. 2015;41(5):419–28.
28.Malm K, Bergman S, Andersson MLE, Bremander A, Larsson I. Quality of life in patients with established rheumatoid arthritis: A phenomenographic study. SAGE Open Med. 2017;5:2050312117713647.
PubMed PubMed Central Google Scholar
29.Katz P. Causes and consequences of fatigue in rheumatoid arthritis. Curr Opin Rheumatol. 2017;29(3):269–76.
30.Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.
PubMed PubMed Central Google Scholar
31.Chimenti MS, Triggianese P, Conigliaro P, Candi E, Melino G, Perricone R. The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death Dis. 2015;6(9):e1887–e.
CAS PubMed PubMed Central Google Scholar
32.Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, et al. 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc Natl Acad Sci U S A. 2014;111(24):E2482–E91.
CAS PubMed PubMed Central Google Scholar
33.Masuko K. Rheumatoid Cachexia Revisited: A Metabolic Co-Morbidity in Rheumatoid Arthritis. Front Nutr. 2014;1:20. https://doi.org/10.3389/fnut.2014.00020.
34.Baillet A, Vaillant M, Guinot M, Juvin R, Gaudin P. Efficacy of resistance exercises in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatology. 2011;51(3):519–27.
35.Khoja SS, Almeida GJ, Chester Wasko M, Terhorst L, Piva SR. Association of Light-Intensity Physical Activity With Lower Cardiovascular Disease Risk Burden in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(4):424–31.
PubMed PubMed Central Google Scholar
36.Tournadre A, Vial G, Capel F, Soubrier M, Boirie Y. Sarcopenia. Joint Bone Spine. 2019;86(3):309–14.
37.Lemmey AB, Marcora SM, Chester K, Wilson S, Casanova F, Maddison PJ. Effects of high-intensity resistance training in patients with rheumatoid arthritis: A randomized controlled trial. Arthritis Care Res (Hoboken). 2009;61(12):1726–34.
38.Banugo P, Amoako D. Prehabilitation. BJA Educ. 2017;17(12):401–5.
39.Duarte-Rojo A, Ruiz-Margáin A, Montaño-Loza AJ, Macías-Rodríguez RU, Ferrando A, Kim WR. Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list. Liver Transplant. 2018;24(1):122–39.
40.Williams AM, Waits S, Englesbe MJ. The Importance of Prehabilitation in Liver Transplantation. Curr Transplant Rep. 2015;2(4):312–5.
41.Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
42.Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S, et al. Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. Adv Ther. 2018;35(10):1535–63.
CAS PubMed PubMed Central Google Scholar
43.Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679–707.
CAS PubMed PubMed Central Google Scholar
44.NICE. Drug treament for rheumatoid arthritis National Institute for Health and Care Excellence. 2021.
45.Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619–35.
46.Roubenoff R, Parise H, Payette HA, Abad LW, D'Agostino R, Jacques PF, et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med. 2003;115(6):429–35.
47.Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: The potential role of an aged immune system. Ageing Res Rev. 2017;36:1–10.
48.Naranjo JD, Dziki JL, Badylak SF. Regenerative Medicine Approaches for Age-Related Muscle Loss and Sarcopenia: A Mini-Review. Gerontology. 2017;63(6):580–9.
留言 (0)